Clinical Trial Update: A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer [Phase 1]

View source ↗

Summary

A Phase I open-label study evaluating the safety and preliminary efficacy of olaparib in combination with carboplatin in advanced HER-2 negative breast cancer w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Lynparza (olaparib)

Snippet

Sponsor: AstraZeneca | Conditions: Breast Cancer | Phase 1 | Status: TERMINATED | Results posted: 2019-02-20